Purple Biotech Stock Forecast, Price & News

+0.02 (+0.52 %)
(As of 05/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume261,188 shs
Average Volume728,222 shs
Market Capitalization$67.94 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PPBT News and Ratings via Email

Sign-up to receive the latest news and ratings for Purple Biotech and its competitors with MarketBeat's FREE daily newsletter.

Purple Biotech logo

About Purple Biotech

Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United States. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension. Its oncology pipeline includes NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. was founded in 2010 and is headquartered in Rehovot, Israel.


See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:PPBT
Phone972 3 933 3121
Year FoundedN/A

Sales & Book Value

Annual Sales$1 million
Book Value$5.56 per share





Market Cap$67.94 million
Next Earnings DateN/A


Overall MarketRank

0.63 out of 5 stars

Medical Sector

1365th out of 2,045 stocks

Pharmaceutical Preparations Industry

591st out of 771 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Purple Biotech (NASDAQ:PPBT) Frequently Asked Questions

Is Purple Biotech a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Purple Biotech in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Purple Biotech stock.
View analyst ratings for Purple Biotech
or view top-rated stocks.

What stocks does MarketBeat like better than Purple Biotech?

Wall Street analysts have given Purple Biotech a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Purple Biotech wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Purple Biotech's key executives?

Purple Biotech's management team includes the following people:
  • Mr. Isaac Israel, CEO & Director (Age 43, Pay $510.1k)
  • Mr. Gil Efron CPA, M.A., Deputy CEO & CFO (Age 55, Pay $380.31k)
  • Dr. Bertrand C. Liang, Chief Medical Officer (Age 58, Pay $446.89k)
  • Dr. Michael Schickler, Head of Clinical Operations (Age 63, Pay $219.14k)
  • Mr. Ido Morpurgo, VP Operations (Age 48)
  • Mr. Simcha Rock CPA, M.B.A., CPA, MBA, Strategic Advisor & Director (Age 71)

Who are some of Purple Biotech's key competitors?

What is Purple Biotech's stock symbol?

Purple Biotech trades on the NASDAQ under the ticker symbol "PPBT."

How do I buy shares of Purple Biotech?

Shares of PPBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Purple Biotech's stock price today?

One share of PPBT stock can currently be purchased for approximately $3.88.

How much money does Purple Biotech make?

Purple Biotech has a market capitalization of $67.94 million and generates $1 million in revenue each year. The company earns $-5,850,000.00 in net income (profit) each year or ($3.00) on an earnings per share basis.

How many employees does Purple Biotech have?

Purple Biotech employs 13 workers across the globe.

What is Purple Biotech's official website?

The official website for Purple Biotech is

Where are Purple Biotech's headquarters?

Purple Biotech is headquartered at ONE AZRIELI CENTER ROUND TOWER 132 MENACHEM BEGIN ROAD, TEL AVIV L3, 6701101.

How can I contact Purple Biotech?

Purple Biotech's mailing address is ONE AZRIELI CENTER ROUND TOWER 132 MENACHEM BEGIN ROAD, TEL AVIV L3, 6701101. The company can be reached via phone at 972 3 933 3121 or via email at [email protected]

This page was last updated on 5/11/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.